3 Growth Stocks That Have Turned $1,000 Into More Than $100,000 in 20 Years
Apple's growth these days is a bit modest, as revenue for the last three months of 2024 was up just 4%, but it still has ...
Leerink Partnrs Has Pessimistic View of REGN Q1 Earnings
Equities research analysts at Leerink Partnrs reduced their Q1 2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued on Tuesday, April 1st. Leerink Partnrs analyst D.
Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks
Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.
Investing Snacks1d
Investors Dose Up on Regeneron Fever
Cannell & Spears LLC boosted its stake in Regeneron Pharmaceuticals by 50.9% last quarter, grabbing 5,415 more shares and ...
Regeneron price target lowered to $925 from $950 at Oppenheimer
Oppenheimer lowered the firm’s price target on Regeneron (REGN) to $925 from $950 and keeps an Outperform rating on the shares. The firm is ...
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Regeneron (REGN – Research Report) and TG ...
Investing Snacks2d
Regeneron’s Glow-Up: Hedge Funds Play Doctor
UniSuper Management Pty Ltd turned up the financial charm, upping its Regeneron stake by 38% in Q4. The fund now owns 7,306 ...
Regeneron Pharmaceuticals (NASDAQ:REGN) Sets New 12-Month Low After Analyst Downgrade
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...
abrdn Healthcare Investors Q4 2024 Commentary
The equity portion of the Abrdn Healthcare Investors Fund fell (gross of fees) but outperformed its custom benchmark over the ...